Slattery John, MacFabe Derrick F, Frye Richard E
Arkansas Children's Research Institute, Little Rock, AR, USA.; Division of Neurology, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
The Kilee Patchell-Evans Autism Research Group, Departments of Psychology (Neuroscience) and Psychiatry, Division of Developmental Disabilities, University of Western Ontario, London, ON, Canada.
Clin Med Insights Pediatr. 2016 Oct 9;10:91-107. doi: 10.4137/CMPed.S38338. eCollection 2016.
Recent studies have highlighted the fact that the enteric microbiome, the trillions of microbes that inhabit the human digestive tract, has a significant effect on health and disease. Methods for manipulating the enteric microbiome, particularly through probiotics and microbial ecosystem transplantation, have undergone some study in clinical trials. We review some of the evidence for microbiome alteration in relation to childhood disease and discuss the clinical trials that have examined the manipulation of the microbiome in an effort to prevent or treat childhood disease with a primary focus on probiotics, prebiotics, and/or synbiotics (ie, probiotics + prebiotics). Studies show that alterations in the microbiome may be a consequence of events occurring during infancy and/or childhood such as prematurity, C-sections, and nosocomial infections. In addition, certain childhood diseases have been associated with microbiome alterations, namely necrotizing enterocolitis, infantile colic, asthma, atopic disease, gastrointestinal disease, diabetes, malnutrition, mood/anxiety disorders, and autism spectrum disorders. Treatment studies suggest that probiotics are potentially protective against the development of some of these diseases. Timing and duration of treatment, the optimal probiotic strain(s), and factors that may alter the composition and function of the microbiome are still in need of further research. Other treatments such as prebiotics, fecal microbial transplantation, and antibiotics have limited evidence. Future translational work, models, long-term and follow-up studies, and guidelines for the composition and viability of probiotic and microbial therapies need to be developed. Overall, there is promising evidence that manipulating the microbiome with probiotics early in life can help prevent or reduce the severity of some childhood diseases, but further research is needed to elucidate biological mechanisms and determine optimal treatments.
最近的研究突出了这样一个事实,即肠道微生物群,也就是栖息在人类消化道中的数万亿微生物,对健康和疾病有着重大影响。操纵肠道微生物群的方法,特别是通过益生菌和微生物生态系统移植,已经在临床试验中得到了一些研究。我们回顾了一些与儿童疾病相关的微生物群改变的证据,并讨论了那些检验了操纵微生物群以预防或治疗儿童疾病的临床试验,主要关注益生菌、益生元,和/或合生元(即益生菌+益生元)。研究表明,微生物群的改变可能是婴儿期和/或儿童期发生的事件的结果,如早产剖腹产和医院感染。此外,某些儿童疾病与微生物群改变有关,即坏死性小肠结肠炎、婴儿腹绞痛、哮喘、特应性疾病、胃肠道疾病、糖尿病、营养不良、情绪/焦虑障碍和自闭症谱系障碍。治疗研究表明,益生菌可能对其中一些疾病的发展具有潜在的保护作用。治疗的时间和持续时间、最佳益生菌菌株,以及可能改变微生物群组成和功能的因素仍需要进一步研究。其他治疗方法,如益生元、粪便微生物移植和抗生素,证据有限。未来需要开展转化研究、建立模型、进行长期和随访研究,并制定益生菌和微生物疗法的组成和活性指南。总体而言有很有前景的证据表明,在生命早期用益生菌操纵微生物群有助于预防或降低某些儿童疾病的严重程度,但需要进一步研究以阐明生物学机制并确定最佳治疗方法。